2009
IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype
Walter O, Prasad M, Lu S, Quinlan R, Edmiston K, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Human Pathology 2009, 40: 1528-1533. PMID: 19695680, DOI: 10.1016/j.humpath.2009.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedNeoplasm ProteinsPhenotypeReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesRNA-Binding ProteinsConceptsHuman epidermal growth factor receptor 2Invasive mammary carcinomaInvasive ductal carcinomaIMP3 expressionNovel biomarkersDuctal carcinomaProgesterone receptorMammary carcinomaBreast cancerEstrogen receptorAggressive phenotypeEpidermal growth factor receptor 2Triple-negative breast cancerDisease-free survivalBiologic prognostic factorsGrowth factor receptor 2Lymph node metastasisInsulin-like growth factor II mRNABasal-like carcinomasGrowth factor II mRNABasal epithelial markersNegative breast cancerBreast cancer casesFactor receptor 2Mouse monoclonal antibodyInsulin-Like Growth Factor mRNA Binding Protein 3 (IMP3) is Differentially Expressed in Benign and Malignant Follicular Patterned Thyroid Tumors
Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A. Insulin-Like Growth Factor mRNA Binding Protein 3 (IMP3) is Differentially Expressed in Benign and Malignant Follicular Patterned Thyroid Tumors. Endocrine Pathology 2009, 20: 149-157. PMID: 19449140, DOI: 10.1007/s12022-009-9079-x.Peer-Reviewed Original ResearchConceptsHürthle cell carcinomaPapillary thyroid carcinomaHürthle cell adenomaFollicular carcinomaGraves' diseaseHashimoto's thyroiditisColloid nodulesFollicular adenomaIMP3 expressionThyroid carcinomaStrong stainingInsulin-like growth factor mRNAThyroid lesionsProtein 3Conventional papillary thyroid carcinomaPathologic tumor characteristicsInsulin-like growth factor IIResidual thyroid tissueSurgical pathology archivesBinding protein 3Thyroid follicular lesionsGrowth factor IIGrowth factor mRNATumor characteristicsUterine cervix
2001
Expression of Melanocytic Differentiation Markers in Malignant Melanomas of the Oral and Sinonasal Mucosa
Prasad M, Jungbluth A, Iversen K, Huvos A, Busam K. Expression of Melanocytic Differentiation Markers in Malignant Melanomas of the Oral and Sinonasal Mucosa. The American Journal Of Surgical Pathology 2001, 25: 782-787. PMID: 11395556, DOI: 10.1097/00000478-200106000-00010.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmDNA-Binding ProteinsGp100 Melanoma AntigenHumansMART-1 AntigenMelanocytesMelanomaMembrane GlycoproteinsMicrophthalmia-Associated Transcription FactorMonophenol MonooxygenaseMouth MucosaMouth NeoplasmsNasal MucosaNeoplasm ProteinsNose NeoplasmsS100 ProteinsTranscription FactorsConceptsHMB-45Mucosal melanomaMucosal tumorsSinonasal mucosaDesmoplastic melanomaImmunohistochemical studyMalignant melanomaOral mucosaSinonasal melanomaSensitive markerMART-1/MelanMelanocytic differentiation antigensOral mucosal tumorsOral mucosal melanomaSinonasal mucosal melanomaMelanocytic differentiation markersRoutine light microscopyNew monoclonal antibodySinonasal tractRare tumorFinal diagnosisMetastatic melanomaDifferentiation antigensMelanomaMucosa